1
|
Kawabata H, Okuno K, Tamura D, Higuchi C, Goldfarb CA. Donor Foot Morbidity Following Nonvascularized Toe Phalanx Transfer Utilizing a New Reconstruction Technique. J Pediatr Orthop 2023:01241398-990000000-00318. [PMID: 37400088 DOI: 10.1097/bpo.0000000000002465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 07/05/2023]
Abstract
BACKGROUNDS Nonvascularized toe phalanx transfer is an accepted surgical option for short and hypoplastic digits in congenital hand abnormalities. However, one of the criticisms of this technique is the donor site morbidity. The purpose of this study was to evaluate donor foot morbidity after nonvascularized toe phalanx transfer using a new donor site reconstruction technique. METHODS We retrospectively reviewed 116 nonvascularized toe phalanx transfers in 69 children between 2001 and 2020 in whom the donor foot was reconstructed with a new technique using iliac osteochondral bone graft with periosteum. Feet treated with an isolated donor proximal phalanx of the fourth toe were selected and morbidity was assessed both subjectively and objectively at a minimum of 2 years after surgery. Motion, stability, and alignment of the metatarsophalangeal joint were clinically evaluated. The relative length of the fourth toe to the third toe was measured on a roentgenogram. The satisfaction of the parents for overall function and appearance was evaluated using a visual analog scale. RESULTS Ninety-four operated feet in 65 patients, including 43 boys and 22 girls, were included. The right foot was evaluated in 52 patients and the left foot in 42 patients. The mean age at operation was 2 years and the mean follow-up period was 7.6 years. Motion at the metatarsophalangeal joint was good at 69% with an average extension of 45 degrees and flexion of 25 degrees. Stability and alignment were good at 95% and 84%, respectively. Only 4 toes had gross instability and 4 toes with poor alignment required revision surgery. Sixty-two toes (66%) maintained proportional length and 9 toes were graded as short. Parental satisfaction was high for appearance as well as function. CONCLUSIONS This newly described technique of using iliac osteochondral bone graft with periosteum to reconstruct toe phalanx donors provided satisfactory results. The function and appearance of the donor foot after a nonvascularized toe phalanx transfer was well preserved. LEVEL OF EVIDENCE Level IV; therapeutic.
Collapse
Affiliation(s)
- Hidehiko Kawabata
- Department of Orthopaedic Surgery, Osaka Rehabilitation Hospital for Children, Higashisumiyoshi-ku, Osaka
| | - Kyoko Okuno
- Department of Orthopaedic Surgery, Osaka Rehabilitation Hospital for Children, Higashisumiyoshi-ku, Osaka
| | - Daisuke Tamura
- Department of Rehabilitation Medicine, Osaka Women's and Children's Hospital, Izumi, Japan
| | - Chikahisa Higuchi
- Department of Rehabilitation Medicine, Osaka Women's and Children's Hospital, Izumi, Japan
| | - Charles A Goldfarb
- Department of Orthopaedic Surgery, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO
| |
Collapse
|
2
|
Hara F, Ono M, Kitano S, Nakayama T, Kawabata H, Watanabe K, Sasaki K, Kataoka T, Saji S, Yonemori K, Shien T, Iwata H. 160TiP A randomized controlled phase III study of bevacizumab and paclitaxel in combination with atezolizumab as a treatment for patients with locally advanced or metastatic hormone receptor-positive HER2-negative breast cancer: JCOG1919E/AMBITION study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Kawabata H, Tamura D, Goldfarb CA. Treatment of Blauth Type IIIB Thumb Hypoplasia Using a Nonvascularized Toe Phalanx. J Hand Surg Am 2021; 46:68.e1-68.e7. [PMID: 32863108 DOI: 10.1016/j.jhsa.2020.07.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Revised: 05/21/2020] [Accepted: 07/15/2020] [Indexed: 02/02/2023]
Abstract
PURPOSE The purpose of this study was to evaluate surgical outcomes of thumb preservation surgery for Blauth type IIIB hypoplastic thumbs using a nonvascularized toe phalanx to reconstruct the carpometacarpal joint. METHODS We reviewed the records of 12 patients with Blauth type IIIB thumb hypoplasia who underwent nonvascularized toe proximal phalanx transfer from the fourth toe. Stability and mobility of the thumb, lateral pinch power, and the percentage of the thumb length relative to the index finger proximal phalanx were evaluated. Outcomes were also assessed with the Functional Dexterity Test, a visual analog scale for daily use of the operated thumb, and for overall functional and appearance satisfaction of the parents. RESULTS Age at operation ranged from 0.9 to 11 years (mean, 3.0 years; median, 1.5 years). The mean follow-up period was 7.6 years (minimum, 3 years). Secondary reconstruction was planned in all 12 patients, but 2 families did not desire a second surgery. Secondary reconstruction consisted of tendon transfer for opposition, adduction, and/or extension of the reconstructed thumb and/or realignment surgery of the thumb axis by arthrodesis or corrective osteotomy. Eleven patients had good carpometacarpal joint stability. Thumb opposition was possible to the little finger in 7, to the middle finger in 3, and not possible in 2 patients. The mean lateral pinch strength was 18% of the contralateral normal side. The relative length of the thumb was 57% of the index finger. Time in seconds to complete Functional Dexterity Test was 83 seconds in the affected side and 38 seconds for the contralateral side. The visual analog scale suggested parental satisfaction for both the appearance and the function. The parents felt that their child used the reconstructed thumb more frequently when manipulating large objects than when manipulating small objects. CONCLUSIONS Nonvascularized toe phalanx transfer is a useful procedure to preserve the thumb in Blauth type IIIB thumb hypoplasia. It provides a mobile, stable thumb that is functionally useful for the child and satisfying for the family. TYPE OF STUDY/LEVEL OF EVIDENCE Therapeutic IV.
Collapse
Affiliation(s)
- Hidehiko Kawabata
- Department of Orthopaedic Surgery, Osaka Rehabilitation Hospital for Children, Osaka.
| | - Daisuke Tamura
- Department of Rehabilitation Medicine, Osaka Women's and Children's Hospital, Izumi, Japan
| | - Charles A Goldfarb
- Department of Orthopaedic Surgery, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO
| |
Collapse
|
4
|
Bando H, Masuda N, Yamanaka T, Kadoya T, Takahashi M, Nagai S, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka T, Uozumi R, Ohno S, Toi M. 163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Kawabata H, Yamashita S, Kikkawa K, Kohjimoto Y, Hara I. Screening of extended spectrum beta-lactamase is useful for preventing acute prostatitis after transrectal ultrasound guided prostate biopsy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33594-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Oka K, Murase T, Tanaka H, Kawabata H. The morphologic change of the elbow with flexion contracture in upper obstetric brachial plexus palsy. J Shoulder Elbow Surg 2019; 28:1764-1770. [PMID: 31043347 DOI: 10.1016/j.jse.2019.02.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Revised: 02/04/2019] [Accepted: 02/15/2019] [Indexed: 02/01/2023]
Abstract
BACKGROUND Contracture of the elbow after obstetric brachial plexus palsy (OBPP) is well known; however, details of the 3-dimensional (3D) morphologic changes in the elbow joint in OBPP have not been clarified. This study aimed to clarify the 3D morphologic changes in the elbow joint by focusing on the distal humerus with flexion contracture in upper OBPP. We tested the hypothesis that the shape of the distal humerus with flexion contracture in upper OBPP is hypoplastic in the trochlea, capitellum, and olecranon fossa. METHODS We retrospectively studied 20 patients with elbow flexion contracture and residual OBPP. The approximate radius of the distal humerus, the shortest distance between the olecranon and coronoid fossa, and the size of the olecranon fossa were measured and compared between the affected and normal sides using 3D bone models to assess the distal humerus morphology. RESULTS The average radius of the distal humerus was smaller on the affected side than on the normal side. Furthermore, the average distance between the olecranon and coronoid fossa was greater and the average size of the olecranon fossa was smaller on the affected side than on the normal side. The size of the distal humerus was significantly smaller and the olecranon fossa was significantly shallower on the affected side. CONCLUSIONS Consistent with our original hypothesis, the distal humerus with flexion contracture in upper OBPP was hypoplastic. The shallow olecranon fossa might prevent full extension of the elbow even though soft tissue contracture release is performed. We recommend evaluation of the morphology of the olecranon fossa to determine the treatment plan for elbow flexion contracture with OBPP.
Collapse
Affiliation(s)
- Kunihiro Oka
- Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
| | - Tsuyoshi Murase
- Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Hiroyuki Tanaka
- Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Hidehiko Kawabata
- Department of Orthopaedic Surgery, Osaka Rehabilitation Hospital for Children, Osaka, Japan
| |
Collapse
|
7
|
Ozaki Y, Takahashi M, Tanabe Y, Miura Y, Tamura N, Shigekawa T, Kawabata H, Baba N, Iguchi H, Takano T. Atypical femoral fracture in breast cancer patients with bone metastasis receiving denosumab therapy: multi-center retrospective analysis. Breast 2019. [DOI: 10.1016/s0960-9776(19)30450-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
8
|
Abstract
BACKGROUND Patients with some thumb polydactyly subtypes are regarded as having a high risk of secondary deformities or poor treatment outcomes. Radially deviated type is one of these subtypes, but its characteristics and definitive treatment outcomes remain unclear. This study aimed to evaluate the pre- and intraoperative findings and surgical outcomes of this subtype. METHODS We identified eight patients with unilateral and proximal phalanx-type polydactyly. The mean age at surgery was 14.6 months, and the mean follow-up period was 7.2 years. We investigated the patients' initial radiograms, surgical procedures and findings, changes in alignment of the retained thumb, and postoperative outcomes using the Japanese Society for Surgery of the Hand scoring system. RESULTS Although the gross appearance of the thumb was a radial deviation, there was an ulnar deviation at the metacarpophalangeal joint on radiography. The ulnar proximal phalanges were delta phalanges in three patients and were connected with the radial proximal phalanges by cartilage in five patients. We retained the ulnar thumbs in all patients and corrected the alignment in seven cases; open wedge osteotomy was performed for three patients with a delta phalanx, and tendon transfers from the radial to ulnar thumb were performed for the other four. The mean outcome score was 17.6/20, with one patient with excellent, six with good, one with fair, and none with poor scores. One patient experienced recurrent radial deviation around the interphalangeal joint five years after surgery and underwent corrective osteotomy, but the other patients maintained good alignment. CONCLUSIONS Radially deviated thumb polydactyly is not simply radially deviated; the shape of the proximal phalanx of the ulnar thumb is important to determine the surgical procedure. However, our results indicated that the alignment is almost manageable, and the surgical outcome was comparable to that of patients with a proximal phalanx-type thumb polydactyly.
Collapse
Affiliation(s)
- Ayumi Suzuki
- 1 Department of Orthopedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
| | - Hidehiko Kawabata
- 1 Department of Orthopedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
| | - Junichiro Hayashi
- 1 Department of Orthopedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
| | - Daisuke Tamura
- 1 Department of Orthopedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
| |
Collapse
|
9
|
Yoshida K, Kawabata H. The prognostic value of concurrent Horner syndrome in surgical decision making at 3 months in total-type neonatal brachial plexus palsy. J Hand Surg Eur Vol 2018; 43:609-612. [PMID: 29747529 DOI: 10.1177/1753193418774265] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
UNLABELLED We investigated the prognostic value of concurrent Horner syndrome for predicting spontaneous motor recovery in surgical decision making at 3 months with neonatal brachial plexus palsy. Medical records of 129 neonates with total-type brachial plexus palsy were reviewed, and clinical and follow-up data of patients with or without Horner syndrome were compared. Twenty-seven of 129 newborn babies with total-type palsy (21%) had concurrent Horner syndrome. Poor spontaneous motor recovery was observed in 21 (78%) neonates with concurrent Horner syndrome and in 84 (82%) without concurrent Horner syndrome. Concurrent Horner syndrome in neonates with brachial plexus palsy has no prognostic value in predicting poor spontaneous motor recovery of the brachial plexus in patients with total-type palsy. LEVEL OF EVIDENCE III.
Collapse
Affiliation(s)
- Kiyoshi Yoshida
- 1 Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Hidehiko Kawabata
- 2 Department of Orthopaedic Surgery, Osaka Rehabilitation Hospital for Children, Osaka, Japan
| |
Collapse
|
10
|
Yoshida K, Kajiura I, Suzuki T, Kawabata H. Natural history of scoliosis in cerebral palsy and risk factors for progression of scoliosis. J Orthop Sci 2018; 23:649-652. [PMID: 29705176 DOI: 10.1016/j.jos.2018.03.009] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2017] [Revised: 02/14/2018] [Accepted: 03/30/2018] [Indexed: 12/24/2022]
Abstract
BACKGROUND Scoliosis in cerebral palsy (CP) often occurs and causes a disturbance in daily life. The purpose of this study was to investigate the natural history of scoliosis in cerebral palsy and determine risk factors for the progression of scoliosis using multivariate analyses. METHODS We revised 113 patients with CP (47 males and 66 females) who had scoliosis with a curve of at least 10° were reviewed and retrospectively investigated these cases of scoliosis and analyzed the risk factors for the progression of this condition. RESULTS The mean follow-up period was 16.5 years and the mean age at onset of scoliosis was 6.6 years (range: 1-16 years). In 59 patients (52%), the age at onset of scoliosis was under 6 years. On the final radiographs, the mean Cobb angle was 55.1° (range: 10° to 169°). After the age of 20 years, 13 of 40 patients (32.5%) had a progression of over 10° in scoliosis. Multivariate analyses showed the risk factors for the progression of scoliosis to be hip displacement (p = 0.0038), the onset of scoliosis before the age of 6 years (p = 0.0024), and 30° of the Cobb angle before the age of 10 years (p < 0.001). A subtype of CP (spastic quadriplegia) was identified as a potential risk factor. CONCLUSIONS After the age of 20 years, 32.5% patients had a progression of over 10° in scoliosis. Risk factors for the progression of scoliosis in CP included hip displacement, early-onset scoliosis, and Cobb angle of 30° before the age of 10 years. LEVEL OF EVIDENCE Prognostic level IV - case series.
Collapse
Affiliation(s)
- Kiyoshi Yoshida
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Japan.
| | - Ichiro Kajiura
- Department of Orthopaedic Surgery, Osaka Rehabilitation Hospital for Children, Japan
| | - Tsunehiko Suzuki
- Department of Orthopaedic Surgery, Osaka Rehabilitation Hospital for Children, Japan
| | - Hidehiko Kawabata
- Department of Orthopaedic Surgery, Osaka Rehabilitation Hospital for Children, Japan
| |
Collapse
|
11
|
Kawabata H, Tamura D. Five- and 10-Year Follow-Up of Nonvascularized Toe Phalanx Transfers. J Hand Surg Am 2018; 43:485.e1-485.e5. [PMID: 29223628 DOI: 10.1016/j.jhsa.2017.10.034] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2017] [Revised: 09/30/2017] [Accepted: 10/31/2017] [Indexed: 02/02/2023]
Abstract
PURPOSE The purpose of this study was to evaluate long-term outcomes of nonvascularized toe phalanx transfer. METHODS We retrospectively reviewed 54 nonvascularized toe phalanx transfers in 29 children with symbrachydactyly. Forty-seven transfers in 24 children were evaluated at 5-year follow-up and 27 transfers in 14 children were evaluated at 10-year follow-up. We recorded the incidence of the early physeal closure and the length of the transferred toe phalanx on plain radiographs at 5- and 10-year follow-up. Growth rate in the first 5 years and the following 5 years were calculated. Function of the metacarpophalangeal joint (motion, stability, and alignment) was also evaluated. RESULTS The mean age at surgery was 1.5 years. Seven toe phalanges were trimmed because the skin pocket was tight. Five transfers required revision surgery for partial necrosis of the skin pocket. At 5-year follow-up, the physis was closed in 23%, and at 10 years, 78% of physes were closed. The phalanx length was 87% of expected at 5-year follow-up and 71% at 10-year follow-up. Growth rate was 0.83 mm/y in the first 5 years and 0.22 mm/y in the following 5 years. Active motion was rated as good in 24, fair in 7, and poor in 16. Stability and alignment were rated as good in 37 and 33, fair in 8 and 5, and poor in 2 and 9, respectively. CONCLUSIONS Nonvascularized toe phalanx transfer offered a relatively simple method to lengthen short digits and to provide satisfactory function. The transferred toe phalanges grew at a near-normal rate in the first 5 years, but the growth rate decreased between 5 and 10 years. TYPE OF STUDY/LEVEL OF EVIDENCE Therapeutic IV.
Collapse
Affiliation(s)
- Hidehiko Kawabata
- Department of Orthopaedic Surgery, Osaka Rehabilitation Hospital for Children, Osaka, Japan.
| | - Daisuke Tamura
- Department of Orthopaedic Surgery, Osaka Women's and Children's Hospital, Osaka, Japan
| |
Collapse
|
12
|
Kawabata H, Azuma K, Ikeda K, Sugitani I, Kinowaki K, Fujii T, Osaki A, Saeki T, Horie-Inoue K, Inoue S. Abstract P3-07-06: TRIM44 is a possible poor prognostic factor for breast cancer patients and positively regulates NF-κB signaling pathway. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-07-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Background]
Many of the tripartite motif (TRIM) proteins, like Efp/TRIM25 which was identified by our group previously (Nature 417, 871-875, 2002), function as E3 ubiquitin ligases, and are thought to be involved in various physiological and pathological processes such as immunity and oncogenesis. In regard to tripartite motif containing 44 (TRIM44), which is an atypical TRIM family protein lacking RING finger domain, some evidences suggest that it is implicated in the progression of several human malignancies. But its pathophysiological significance in breast cancer remains unknown.
[Methods]
In the present study, immunohistochemical analysis using anti-TRIM44 antibody was performed in clinical breast cancer tissues from 129 patients with the approval of institutional ethical committees (approval number: 845). We then explored the pathophysiological role of TRIM44 in breast cancer by modulating TRIM44 expression in MCF-7 and MDA-MB-231 breast cancer cells.
[Results]
TRIM44 strong immunoreactivity was significantly associated with nuclear grade, distant disease-free survival and overall survival of the breast cancer patients. With multivariate analysis it was shown that the TRIM44 status was an independent prognostic factor for distant disease-free survival and overall survival. The proliferation of MCF-7 and MDA-MB-231 cells was significantly decreased by siRNA-mediated TRIM44 knockdown. TRIM44 knockdown also suppressed migration of MDA-MB-231 cells. Microarray analysis and qRT-PCR revealed that TRIM44 knockdown upregulated CDK19 (Cyclin Dependent Kinase 19), which is reported to be a tumor suppressor gene, whereas downregulated MMP1 (Matrix Metallopeptidase 1) in MDA-MB-231 cells. Notably, TRIM44 knockdown impaired nuclear factor-kappa B (NF-κB)-mediated transcriptional activity stimulated by tumor necrosis factor α (TNFα). Moreover, TRIM44 knockdown substantially attenuated the TNFα-dependent phosphorylation of p65 subunit of NF-κB and IκBα in both MCF-7 and MDA-MB-231 cells.
[Discussion]
Our clinical study showed that prognosis of breast cancer patients is correlated with the immunoreactivity detected by anti-TRIM44 antibody. This result suggested that expression of TRIM44 protein could be used as a potential biomarker of breast cancer. We demonstrated that NF-κB signaling pathway is modulated by TRIM44. Since NF-κB augmentation is shown to be related to aggressive character of breast cancer, stimulation of NF-κB signaling with TRIM44 might be underlying mechanism of poor prognosis. Our in vitro study showed TRIM44 knockdown caused attenuated proliferation and migration of breast cancer cells, raising the possibility of TRIM44 as a potential therapeutic target for breast cancer. These findings provide new clues to develop alternative effective strategies for breast cancer management.
Citation Format: Kawabata H, Azuma K, Ikeda K, Sugitani I, Kinowaki K, Fujii T, Osaki A, Saeki T, Horie-Inoue K, Inoue S. TRIM44 is a possible poor prognostic factor for breast cancer patients and positively regulates NF-κB signaling pathway [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-07-06.
Collapse
Affiliation(s)
- H Kawabata
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - K Azuma
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - K Ikeda
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - I Sugitani
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - K Kinowaki
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - T Fujii
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - A Osaki
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - T Saeki
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - K Horie-Inoue
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| | - S Inoue
- Tokyo Metropolitan Institue of Gerontology, Tokyo, Itabashi-ku, Japan; Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Toranomon Hospital, Minato-ku, Tokyo, Japan
| |
Collapse
|
13
|
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. Abstract P4-21-14: A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.
Citation Format: Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-14.
Collapse
Affiliation(s)
- T Takano
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - J Tsurutani
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - M Takahashi
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - T Yamanaka
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Sakai
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - Y Ito
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - J Fukuoka
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - H Kimura
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - H Kawabata
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Tamura
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Matsumoto
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Aogi
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Sato
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Nishio
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Nakagawa
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - T Saeki
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| |
Collapse
|
14
|
Tsurutani J, Sakai K, Takao T, Kimura H, Kawabata H, Tanaka K, Takahashi M, Ito Y, Takao S, Aogi K, Sato K, Tsuji Y, Yamanaka T, Nakanishi Y, Saeki T, Nishio K. Abstract P2-05-24: Prognostic value of circulating PIK3CA mutations revealed with digital PCR in patients with HER2-positive advanced breast cancer: Results of West Japan Oncology Group study 6110BTR. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- J Tsurutani
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Sakai
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - T Takao
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - H Kimura
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - H Kawabata
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Tanaka
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - M Takahashi
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Y Ito
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - S Takao
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Aogi
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Sato
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Y Tsuji
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - T Yamanaka
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Y Nakanishi
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - T Saeki
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Nishio
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| |
Collapse
|
15
|
Kikuchi Y, Uchida Y, Kanauchi H, Niwa T, Nishioka K, Tada K, Hashimoto M, Yasuda H, Kawabata H, Seto Y, Ogawa T. 135P A multicenter retrospective observation study about overall survival benefit of eribulin mesylate in comparison with taxane regimens for metastatic cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw577.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Kikuchi Y, Uchida Y, Kanauchi H, Niwa T, Nishioka K, Tada K, Hashimoto M, Yasuda H, Kawabata H, Seto Y, Ogawa T. 135P A multicenter retrospective observation study about overall survival benefit of eribulin mesylate in comparison with taxane regimens for metastatic cancer patients. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00293-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
17
|
Tanabe Y, Shiraishi S, Nishizawa D, Hamada A, Hasegawa J, Ozaki Y, Tamura N, Shimomura A, Yunokawa M, Yonemori K, Takano T, Kawabata H, Ikeda K, Tamura K, Fujiwara Y, Shimizu C. Paclitaxel-induced sensory peripheral neuropathy is associated with a SCN9A variant. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Suzuki J, Hashino M, Matsumoto S, Takano A, Kawabata H, Takada N, Andoh M, Oikawa Y, Kajita H, Uda A, Watanabe K, Shimizu T, Watarai M. Detection of Francisella tularensis and analysis of bacterial growth in ticks in Japan. Lett Appl Microbiol 2016; 63:240-6. [PMID: 27432517 DOI: 10.1111/lam.12616] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Revised: 07/13/2016] [Accepted: 07/14/2016] [Indexed: 11/28/2022]
Abstract
UNLABELLED Francisella tularensis is distributed in the Northern hemisphere and it is the bacterial agent responsible for tularaemia, a zoonotic disease. We collected 4 527 samples of DNA from ticks in Japan, which were then analysed by real-time PCR and nested PCR. Francisella DNA was detected by real-time PCR in 2·15% (45/2 093) of Ixodes ovatus, 0·66% (14/2 107) of I. persulcatus, 8·22% (6/73) of I. monospinosus and 0·72% (1/138) of Haemaphysalis flava specimens. Finally, Francisella DNA was detected by nested PCR in 42 and five samples I. ovatus and I. persulcatus, respectively, which were positive according to real-time PCR. Phylogenetic analysis showed that the sequence from I. ovatus and I. persulcatus were clustered with F. tularensis type B strains distributed in Eurasia. Microinjected live F. tularensis persisted in ticks, whereas heat-killed F. tularensis decreased. Microinjected F. tularensis hlyD mutant decreased in ticks significantly compared to parent strain, thereby suggesting that HlyD in F. tularensis contributes to the adaptation or survive of bacterial infection in ticks. SIGNIFICANCE AND IMPACTS OF THE STUDY Francisella tularensis has been detected in ticks, suggesting that it is a tick-borne pathogen. However, F. tularensis has not been detected in ticks in Japan since 1991. In this study, we performed a large-scale analysis of DNA isolated from ticks in Japan and detected F. tularensis by real-time polymerase chain reaction (PCR) and nested PCR. We found that F. tularensis could survive in ticks based on an experimental tick-infection model. We also identified a bacterial factor that contributes to survival in ticks. Our results suggest that ticks are candidate vectors that mediate F. tularensis infection in Japan.
Collapse
Affiliation(s)
- J Suzuki
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - M Hashino
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - S Matsumoto
- Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - A Takano
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.,Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - H Kawabata
- Laboratory of Systemic Infection, Department of Bacteriology-I, National Institute of Infectious Diseases, Tokyo, Japan
| | - N Takada
- Faculty of Medical Science, University of Fukui, Eiheiji, Fukui, Japan
| | - M Andoh
- Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan
| | - Y Oikawa
- Department of Medical Zoology, Kanazawa Medical University, Kahoku, Ishikawa, Japan
| | - H Kajita
- Meat Inspection Center of Iwate Prefecture, Iwate, Japan
| | - A Uda
- Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan
| | - K Watanabe
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.,Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - T Shimizu
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.,Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - M Watarai
- The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan. .,Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
| |
Collapse
|
19
|
Suissa S, Baker N, Kawabata H, Ray N, Simon T. SAT0150 Comparative Risk of Malignancy with Initiaton of Abatacept and Other Biologics in Patients with Rheumatoid Arthritis: A Cohort Analysis of A United States Claims Database. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1275] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
20
|
Baker N, Boers M, Hochberg M, Kawabata H, Ray N, Simon T. FRI0229 Risk of Hospitalized Infections in Patients with Rheumatoid Arthritis Initiating Abatacept and Other Biologics: Analysis of A United States Claims Database. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
21
|
Ishiyama K, Takeda J, Kondo T, Sugimoto N, Kawabata H, Kitano T, Takaori-Kondo A. Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation. Bone Marrow Transplant 2016; 51:985-7. [PMID: 26878662 DOI: 10.1038/bmt.2016.16] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- K Ishiyama
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - J Takeda
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Kondo
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - N Sugimoto
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.,Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
| | - H Kawabata
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - T Kitano
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - A Takaori-Kondo
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
22
|
Ozaki Y, Tamura N, Utiyama M, Masuda J, Koganemaru S, Miura Y, Tanabe Y, Ogura T, Kadowaki M, Miura D, Kawabata H, Takano T. Abstract P5-12-11: Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: Retrospective study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-12-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although tamoxifen (TAM) plus ovarian function suppression (OFS) is one of standard adjuvant treatments in premenopausal women with hormone receptor-positive breast cancer, the optimal duration of OFS has not been clearly established.
Patients and Methods: We retrospectively reviewed data of premenopausal patients with breast cancer, who received TAM and OFS (goserelin or leuprorelin) as adjuvant therapy between February 2004 and April 2015. The primary analysis was to compare disease-free survival (DFS) between patients who received OFS shorter than 3 years and those who received OFS longer than 3 years. The analyses were performed with Cox proportional hazards models and propensity score matching models.
Results: We analyzed 206 premenopausal patients with hormone receptor-positive breast cancer. Median follow-up time was 56 months. Median age was 42 years (range, 24-52 years). Twenty six per cent of the patients had positive axillary nodes and 30% had received neo-adjuvant or adjuvant chemotherapy. Median duration of OFS was 26 months. Duration of OFS was shorter than three years (OFS < 3y) in 74% patients, and longer than three years (OFS > 3y) in 26% patients. Patients with node-positive disease were more in OFS > 3y group than in OFS < 3y group, and more patients received chemotherapy in OFS > 3y group than in OFS < 3y group. 5-year disease-free survival (DFS) was 96.1%. DFS in patients aged ≤ 40 years and aged > 40 years were 91.8% and 99.0%, respectively (p=0.0223). Propensity score matching model showed that DFS was not significantly different between patients in OFS < 3y group and those in OFS > 3y group (97.4%, 91.6%; p=0.2406). In patients aged ≤ 40 years and/or those who received chemotherapy, 5-year DFS was 96.7% in OFS < 3y group, 90.1% in OFS > 3y group (p=0.3011).
Conclusions: Our data suggest that OFS < 3y is not inferior to OFS > 3y for premenopausal women with hormone receptor-positive breast cancer as adjuvant endocrine therapy. A randomized trial is needed to establish the optimal OFS duration for these patients.
Citation Format: Ozaki Y, Tamura N, Utiyama M, Masuda J, Koganemaru S, Miura Y, Tanabe Y, Ogura T, Kadowaki M, Miura D, Kawabata H, Takano T. Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: Retrospective study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-12-11.
Collapse
Affiliation(s)
- Y Ozaki
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - N Tamura
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - M Utiyama
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - J Masuda
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - S Koganemaru
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - Y Miura
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - Y Tanabe
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - T Ogura
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - M Kadowaki
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - D Miura
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - H Kawabata
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| | - T Takano
- Toranomon Hospital, 2-2-2 Toranomon Minato-ku, Tokyo, Japan
| |
Collapse
|
23
|
Masuda J, Ozaki Y, Nakajima H, Oki R, Uchiyama M, Koganemaru S, Ogura T, Tamura N, Miura Y, Tanabe Y, Miura D, Kawabata H, Takano T. 104P Feasibility of dose-dense doxorubicin and cyclophosphamide (ddAC) followed by taxane (T) in Japanese women with early breast cancer: A retrospective study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Murakami Y, Kawabata H, Takeuchi Y, Doi Y, Okabe T, Kenjo M, Kimura T, Nagata Y. Incidence and Clinical Features of Metachronous Esophageal Cancer After Definitive Radiation Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Kubo K, Kimura T, Sakaguchi H, Imano N, Kawabata H, Takeuchi Y, Doi Y, Okabe T, Kenjo M, Ozawa S, Murakami Y, Nagata Y. Computed Tomographic Appearance of Radiation Injuries in Lung After Two Prescribed Dose of 48Gy With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Imano N, Kimura T, Nishibuchi I, Nakashima T, Kubo K, Sakaguchi H, Kawabata H, Takeuchi Y, Doi Y, Okabe T, Kenjo M, Ozawa S, Murakami Y, Nagata Y. A Quantitative Index for Phase Selection in Planning of Respiratory Gating Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Abe K, Iyogi T, Kawabata H, Chiang JH, Suwa H, Hisamatsu S. Estimation of 85Kr dispersion from the spent nuclear fuel reprocessing plant in Rokkasho, Japan, using an atmospheric dispersion model. Radiat Prot Dosimetry 2015; 167:331-335. [PMID: 25948824 DOI: 10.1093/rpd/ncv273] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The spent nuclear fuel reprocessing plant of Japan Nuclear Fuel Limited (JNFL) located in Rokkasho, Japan, discharged small amounts of (85)Kr into the atmosphere during final tests of the plant with actual spent fuel from 31 March 2006 to October 2008. During this period, the gamma-ray dose rates due to discharged (85)Kr were higher than the background rates measured at the Institute for Environmental Sciences and at seven monitoring stations of the Aomori prefectural government and JNFL. The dispersion of (85)Kr was simulated by means of the fifth-generation Penn State/NCAR Mesoscale Model and the CG-MATHEW/ADPIC models (ver. 5.0) with a vertical terrain-following height coordinate. Although the simulated gamma-ray dose rates due to discharged (85)Kr agreed fairly well with measured rates, the agreement between the estimated monthly mean (85)Kr concentrations and the observed concentrations was poor. Improvement of the vertical flow of air may lead to better estimation of (85)Kr dispersion.
Collapse
Affiliation(s)
- K Abe
- Institute for Environmental Sciences, 1-7 Ienomae, Obuchi, Rokkasho, Aomori, Japan
| | - T Iyogi
- Institute for Environmental Sciences, 1-7 Ienomae, Obuchi, Rokkasho, Aomori, Japan
| | - H Kawabata
- Institute for Environmental Sciences, 1-7 Ienomae, Obuchi, Rokkasho, Aomori, Japan
| | - J H Chiang
- Japan NUS Co. Ltd., Nishi-Shinjuku Kimuraya Building 5F, 7-5-25 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan
| | - H Suwa
- Japan NUS Co. Ltd., Nishi-Shinjuku Kimuraya Building 5F, 7-5-25 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan
| | - S Hisamatsu
- Institute for Environmental Sciences, 1-7 Ienomae, Obuchi, Rokkasho, Aomori, Japan
| |
Collapse
|
28
|
Takeuchi Y, Murakami Y, Kubo K, Sakaguchi H, Imano N, Kawabata H, Doi Y, Okabe T, Kenjo M, Kimura T, Nagata Y, Fujita M, Konishi M. Interstitial Brachytherapy for Early-Stage Tongue Cancer: Analysis of the Long-term Treatment Results for Survival and Complications. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Simon T, Kawabata H, Esdaile J, Moorthy V, Suissa S. FRI0371 Autoimmune Diseases in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Suissa S, Baker N, Ravindran A, Kawabata H, Simon T. THU0366 Characteristics of Patients Initiating Abatacept for the Treatment of Rheumatoid Arthritis in the Real World: Methodological Challenges for Comparative Safety Studies. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
Baker N, Suissa S, Kawabata H, Skovron M, Moorthy V, Simon T. AB0474 Identification of Tuberculosis Incidence Through the Use of a Validated Claims-Based Algorithm Among Rheumatoid Arthritis Patients Treated with Disease-Modifying Antirheumatic Drugs. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Yoshida K, Kawabata H. The prognostic value of concurrent phrenic nerve palsy in newborn babies with neonatal brachial plexus palsy. J Hand Surg Am 2015; 40:1166-9. [PMID: 25804363 DOI: 10.1016/j.jhsa.2015.01.039] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Revised: 01/29/2015] [Accepted: 01/31/2015] [Indexed: 02/02/2023]
Abstract
PURPOSE To investigate the prognostic value of concurrent phrenic nerve palsy for predicting spontaneous motor recovery in neonatal brachial plexus palsy. METHODS We reviewed the records of 366 neonates with brachial plexus palsy. The clinical and follow-up data of patients with and without phrenic nerve palsy were compared. RESULTS Of 366 newborn babies with neonatal brachial plexus palsy, 21 (6%) had concurrent phrenic nerve palsy. Sixteen of these neonates had upper-type palsy and 5 had total-type palsy. Poor spontaneous motor recovery was observed in 13 neonates with concurrent phrenic nerve palsy (62%) and in 129 without concurrent phrenic nerve palsy (39%). Among neonates born via vertex delivery, poor motor recovery was observed in 7 of 9 (78%) neonates with concurrent phrenic nerve palsy and 115 of 296 (39%) without concurrent phrenic nerve palsy. CONCLUSIONS Concurrent phrenic nerve palsy in neonates with brachial plexus palsy has prognostic value in predicting poor spontaneous motor recovery of the brachial plexus, particularly after vertex delivery. TYPE OF STUDY/LEVEL OF EVIDENCE Therapeutic IV.
Collapse
Affiliation(s)
- Kiyoshi Yoshida
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
| | - Hidehiko Kawabata
- Department of Orthopaedic Surgery, Osaka Medical Center and Research, Osaka, Japan
| |
Collapse
|
33
|
Kachroo S, Pan X, Liu L, Kawabata H, Phatak H. Clinical and Demographics Characteristics of Non-Valvular Atrial Fibrillation Patients Switching From Warfarin To Novel Oral Anticoagulants. Value Health 2014; 17:A500-A501. [PMID: 27201512 DOI: 10.1016/j.jval.2014.08.1506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- S Kachroo
- Bristol-Myers Squibb Company, Princeton, NJ, USA
| | - X Pan
- Bristol-Myers Squibb, New Haven, CT, USA
| | - L Liu
- Pfizer, New York, NY, USA
| | | | - H Phatak
- Bristol-Myers Squibb Company, Princeton, NJ, USA
| |
Collapse
|
34
|
Kawakami M, Sato S, Miyabe Y, Tanabe K, Nishimura M, Tsuji M, Murakami Y, Kawabata H, Fushiki M. Development of Error Estimating Program for IMRT Dose Delivery Using Dynamic MLC Log Files. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Hidano A, Konnai S, Yamada S, Githaka N, Isezaki M, Higuchi H, Nagahata H, Ito T, Takano A, Ando S, Kawabata H, Murata S, Ohahsi K. Suppressive effects of neutrophil by Salp16-like salivary gland proteins from Ixodes persulcatus Schulze tick. Insect Mol Biol 2014; 23:466-474. [PMID: 24698498 DOI: 10.1111/imb.12101] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Salp16, a 16-kDa tick salivary gland protein, is known to be the molecule involved in the transmission of Anaplasma phagocytophilum, an obligate intracellular pathogen causing zoonotic anaplasmosis, from its mammalian hosts to Ixodes scapularis. Recently, the presence of A. phagocytophilum was documented in Japan and Ixodes persulcatus was identified as one of its vectors. The purpose of this study was to identify Salp16 genes in I. persulcatus and characterize their function. Two cDNA clones encoding the Salp16-like sequences were obtained from the salivary glands of fed female I. persulcatus ticks and designated Salp16 Iper1 and Iper2. Gene expression analyses showed that the Salp16 Iper genes were expressed specifically in the salivary glands and were up-regulated by blood feeding. These proteins attenuated the oxidative burst of activated bovine neutrophils and inhibited their migration induced by the chemoattractant interleukin-8 (IL-8). These results demonstrate that Salp16 Iper proteins contribute to the establishment of blood feeding as an immunosuppressant of neutrophil, an essential factor in innate host immunity. Further examination of the role of Salp16 Iper in the transmission of pathogens, including A. phagocytophilum, will increase our understanding of the tick-host-pathogen interface.
Collapse
Affiliation(s)
- A Hidano
- Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Alemao E, Joo S, Kawabata H, Al M, Allison P, Rutten-van Molken M, Frits M, Iannaccone C, Shadick N, Weinblatt M. THU0246 Differences (OR Variations) in Physical Functioning in RA by Disease Activity Levels Defined by Das, CDai, and SDAI in Clinical Practice. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Rajagopalan V, Alemao E, Kawabata H, Solomon D. SAT0069 Performance of the Framingham Cardiovascular Risk Prediction Model with and without C-Reactive Protein or Erythrocyte Sedimentation Rate in RA: Analysis of US Electronic Medical Records Database. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1833] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
An J, Alemao E, Cheetham T, Reynolds K, Kawabata H, Solomon D. SAT0044 The Role of C-Reactive Protein or Erythrocyte Sedimentation Rate in Predicting Cardiovascular Outcomes in Rheumatoid Arthritis: Analysis of Data from US Managed Care Organization. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Alemao E, Joo S, Kawabata H, Al M, Allison P, Rutten-van Molken M, Frits M, Iannaccone C, Shadick N, Weinblatt M. FRI0003 Quality of Life and Economic Benefits of Remission/Low Disease Activity in Patients with Rheumatoid Arthritis in Clinical Practice Setting. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Res Treat 2014; 145:143-53. [PMID: 24682674 DOI: 10.1007/s10549-014-2907-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 03/04/2014] [Indexed: 10/25/2022]
Abstract
We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evaluated using multivariate analyses. The 3-year DFS rate was 87 % [95 % confidence interval (CI) 85-90]. The pathologic complete response (pCR: ypT0/is + ypN0) rate was 51 %. The pCR rate was higher in the ER/PgR-negative patients than in the ER/PgR-positive patients (64 vs. 36 %, P < 0.001). Patients with pCR showed a higher DFS rate than patients without pCR (93 vs. 82 %, P < 0.001). Multivariate analysis revealed three independent predictors for poorer DFS: advanced nodal stage [hazard ratio (HR) 2.63, 95 % CI 1.36-5.21, P = 0.004 for cN2-3 vs. cN0], histological/nuclear grade 3 (HR 1.81, 95 % CI 1.15-2.91, P = 0.011), and non-pCR (HR 1.98, 95 % CI 1.22-3.24, P = 0.005). In the ER/PgR-negative dataset, non-pCR (HR 2.63, 95 % CI 1.43-4.90, P = 0.002) and clinical tumor stage (HR 2.20, 95 % CI 1.16-4.20, P = 0.017 for cT3-4 vs. cT1-2) were independent predictors for DFS, and in the ER/PgR-positive dataset, histological grade of 3 (HR 3.09, 95 % CI 1.48-6.62, P = 0.003), clinical nodal stage (HR 4.26, 95 % CI 1.53-13.14, P = 0.005 for cN2-3 vs. cN0), and young age (HR 2.40, 95 % CI 1.12-4.94, P = 0.026 for ≤40 vs. >40) were negative predictors for DFS. Strict pCR (ypT0 + ypN0) was an independent predictor for DFS in both the ER/PgR-negative and -positive datasets (HR 2.66, 95 % CI 1.31-5.97, P = 0.006 and HR 3.86, 95 % CI 1.13-24.21, P = 0.029, respectively). These results may help assure a more accurate prognosis and personalized treatment for HER2-positive breast cancer patients.
Collapse
Affiliation(s)
- M Takada
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Abstract P6-06-20: Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND:
Addition of trastuzumab to neoadjuvant chemotherapy (NAC) improved pathologic complete response (pCR) rate in HER2-positive breast cancer. Although recent trials have shown favorable prognosis with NAC plus trastuzumab, clinicopathological factors to predict the outcome have not been fully understood. The aim of this study was to investigate the survival after NAC with trastuzumab and to explore the predictive factors.
PATIENTS AND METHODS:
This is a multicenter retrospective observational study. Patients with HER2-positive primary breast cancer treated with NAC plus trastuzumab from 2001 to 2010 were identified from the institutional database. Primary end point was disease-free survival (DFS). pCR was defined as ypT0/is+ypN0. Kaplan-Meier method was used to estimate DFS. Logistic regression and proportional hazard analysis were used to identify clinicopathological factors to predict pCR and DFS, respectively.
RESULTS:
733 patients were included in the analysis (whole dataset). 425 were ER/PgR-negative (HR- dataset) and 306 were ER/PgR-positive (HR+ dataset). Radiation therapy was performed in 90% of lumpectomy and 31% of mastectomy. Hormonal therapy was performed in 84% of HR+ dataset. pCR rate was 45% in whole dataset, 60% in HR- dataset, and 34% in HR+ dataset. Table 1 showed the result of multivariate analysis for pCR in whole dataset. When HR+ and HR- dataset were analyzed separately, no definitive predictors for pCR were identified in multivariate analysis. Although the patients with pCR showed a significantly favorable prognosis than those without pCR at 3 years DFS, in whole dataset (93% vs 83%, p<0.0001) and HR- dataset (94% vs 80%, p<0.0001), there was no significant difference in HR+ dataset (89% vs 86%, p = 0.10). Different predictors were selected for DFS when multivariate analysis was conducted separately between HR- and HR+ dataset (Table 2).
CONCLUSIONS:
In this observational study, we clarified predictors for pCR and DFS in HER2-positive patients treated with neoadjuvant trastuzumab containing therapy based on tumor subtype. Our results may help us to predict the prognosis more precisely and to simulate the disease course.
Table 1) Multivariate logistic regression analysis for pCR in whole datasetFactorsOR95%CIp-valuePost- vs Pre-menopause1.50(1.05-2.15)0.026*cT1-2 vs cT3-41.72(1.16-2.59)0.008*ER/PgR-negative vs ER/PgR-positive3.32(2.30-4.82)<0.0001*Grade 3 vs 1-21.28(0.89-1.84)0.183
Table 2) Multivariate proportional hazard analysis for DFSFactors†HR95%CIp-valueWhole dataset Pre- vs Post-menopause1.61(1.04-2.52)0.033*cN2-3 vs cN03.06(1.58-6.24)0.001*cN1 vs cN02.26(1.23-4.41)0.007*Grade 3 vs 1-21.87(1.20-2.97)0.006*non-pCR vs pCR1.90(1.18-3.13)0.008*HR- dataset Pre- vs Post-menopause1.70(1.01-2.85)0.046*cT3-4 vs cT1-21.86(1.09-3.17)0.024*non-pCR vs pCR3.28(1.90-5.87)<0.0001*HR+ dataset cN2-3 vs cN05.01(1.79-16.19)0.002*cN1 vs cN03.50(1.40-10.61)0.006*Grade 3 vs 1-22.95(1.52-5.87)0.001*†Only factors with statistical significance
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-20.
Collapse
Affiliation(s)
- M Takada
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Ishiguro
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Nagai
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Ohtani
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Kawabata
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Yanagita
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Hozumi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - C Shimizu
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Takao
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - N Sato
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Kosaka
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Sagara
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Iwata
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Ohno
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - K Kuroi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - N Masuda
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Yamashiro
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Sugimoto
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Kondo
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Naito
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Sasano
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - T Inamoto
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Morita
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Toi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| |
Collapse
|
42
|
Kawabata H, Kakihara N, Atsuta H, Taga C, Nakamae C, Inamitsu H, Inoda H, Nishikawa M. Cooperation with Other Clinical Departments in Intervention of Palliative Care Team in Our Hospital. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Pan X, Kawabata H, Hamilton M, Liu X. Patient characteristics associated with the initiation of novel oral anticoagulants versus warfarin in patients with atrial fibrillation. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.p543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Masuda N, Sato N, Higaki K, Kashiwaba M, Matsunami N, Takano T, Yamamura J, Kaneko K, Takahashi M, Ohno S, Fujisawa T, Tsuyuki S, Miyoshi Y, Ohtani S, Yamamoto Y, Bando H, Onoda T, Kawabata H, Morita S, Ueno T, Toi M. Abstract P1-14-08: A prospective multicenter randomized phase II neo-adjuvant study of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) followed by docetaxel, cyclophosphamide and trastuzumab (TCH) versus TCH followed by FEC versus TCH alone, in patients (pts) with operable HER2 positive breast cancer: JBCRG-10 study. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-14-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The current standard treatment of primary systemic therapy (PST) in HER2 positive breast cancer is anthracyclines (A) and/or taxanes combined with trastuzumab (H) which demonstrates high pathological complete response (pCR). The pCR is considered as a predictive marker of prognosis although results are slightly different depending on the hormone receptor status. We conducted a randomized phase II study to examine sequence of treatments and necessity of A in the treatments using TCH to improve outcome and reduce cardiac toxicity in Japanese HER2 positive pts.
Methods: Pts were treated with FEC (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) and/or TCH (docetaxel 75 mg/m2, cyclophosphamide 600 mg/m2, H 6 mg/kg, loading by 8 mg) in 3 groups: 4 cycles of FEC followed by 4 cycles of TCH (A-TCH); 4 cycles of TCH followed by 4 cycles of FEC (TCH-A) or 6 cycles of TCH. An unplanned interim analysis was conducted due to one death by interstitial lung disease (ILD) in the A-TCH after completion of 8 cycles. The pCR results suggested A containing regimens did not exceed benefit from the current standard regimen. The study was continued by limiting allocation only to the TCH group considering efficacy and safety. The primary endpoint was pCR and secondary endpoints were overall response rate (ORR) and safety.
Results: A total of 103 pts were enrolled between Sep. 2009 and Sep. 2011; 21 pts in the A-TCH, 22 pts in the TCH-A and 60 pts in the TCH including pts enrolled after termination of random allocation. Characteristics of the 103 pts were; median age of 54 (range, 33–70), median tumor size of 35 mm (range, 12–80), 42 pts with N(+) (40.8%) and 62 ER positive pts (60.2%). Characteristics of pts in the TCH were; median age of 54.5 (range, 33–67), median tumor size of 35.5 mm (range, 12–80), 25 pts with N(+) (41.7%) and 34 ER positive pts (56.7%). No major difference was reported between groups treated with or without A. Per protocol population was 59 pts in the TCH and its pCR rate was 45.8% (95% CI, 32.2–59.3: ER negative, 61.5%; ER positive, 33.3%). ORR was 86.4% assessed by MRI or CT. Although it is an exploratory analysis, the pCR rate of A containing regimens was 39.0% (ER negative, 57.1%; ER positive, 29.6%). Adverse events ≥grade 3 were reported in 50 pts (48.5%). Reported ILD was in 5 pts (A-TCH, 1; TCH-A, 1; TCH, 3). The mean left ventricular ejection fraction (LVEF) decreased from 70.0% to 69.0% after treatment (A-TCH, 65.9%; TCH-A, 70.4%; TCH, 69.0%). Decrease of LVEF in the A-TCH was significant (p < 0.01).
Conclusion: The pCR rate of the TCH group was similar to previous reports on A including regimens. Although ILD had been occurred during the treatment containing the TCH, no other new safety issues were reported. We were not able to conclude preferable sequence of A and T since statistical power was not sufficient. However, the result of LVEF suggested TCH followed by A or TCH were preferable. Six cycles of TCH could be one of treatment options as a PST in HER2 positive breast cancer to exclude A. (UMIN000002365)
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-08.
Collapse
Affiliation(s)
- N Masuda
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - N Sato
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - K Higaki
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - M Kashiwaba
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - N Matsunami
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Takano
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - J Yamamura
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - K Kaneko
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - M Takahashi
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Ohno
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Fujisawa
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Tsuyuki
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - Y Miyoshi
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Ohtani
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - Y Yamamoto
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - H Bando
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Onoda
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - H Kawabata
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Morita
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Ueno
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - M Toi
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| |
Collapse
|
45
|
Niihata K, Tomosugi N, Uehata T, Shoji T, Mitsumoto K, Shimizu M, Kawabata H, Sakaguchi Y, Suzuki A, Hayashi T, Okada N, Isaka Y, Rakugi H, Tsubakihara Y. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease. Nephrol Dial Transplant 2012; 27:4378-85; discussion 4384-5. [DOI: 10.1093/ndt/gfs322] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|
46
|
Miura D, Hanaoka M, Shimomura A, Iwatani T, Kawabata H, Fujii T. 442 Are There Any Differences of Biomarker Changes in Short Term Neoadjuvant Ais (Exemestane Vs. Letrozole)? Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70508-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Abstract
Growth disturbance of the paralytic limb was analyzed in 50 patients with newborn brachial plexus palsy. The ratio of the bone length on the paralyzed side to that on the normal side as depicted on the roentogenogram was calculated at the average age of 7.2 years. While in upper type palsy the ratio was 95% in the humerus, 97% in the radius, and 96% in the ulna, that in total type palsy was 93%, 89%, and 88%, respectively. In mild paralysis, it was 95%, 98%, and 97%, respectively, while in severe paralysis, it was 93%, 88%, and 88%, respectively. In those who underwent neurosurgical reconstruction, it was 94%, 93%, and 92%, respectively, while in those who did not, it was 92%, 84%, and 85%, respectively. The degree of shortening was well correlated with the extent and severity of paralysis, and early neurosurgical reconstruction was found to reduce it.
Collapse
Affiliation(s)
- Yasuhiko Hamada
- Department of Orthopaedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, 840 Murodo-cho, Izumi, Osaka 590-02, Japan
| | - Hidehiko Kawabata
- Department of Orthopaedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, 840 Murodo-cho, Izumi, Osaka 590-02, Japan
| | - Natsuo Yasui
- Department of Orthopaedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, 840 Murodo-cho, Izumi, Osaka 590-02, Japan
| | - Motohiro Kitano
- Department of Orthopaedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, 840 Murodo-cho, Izumi, Osaka 590-02, Japan
| | - Takashi Masatomi
- Department of Orthopaedic Surgery, Osaka Medical Center and Research Institute for Maternal and Child Health, 840 Murodo-cho, Izumi, Osaka 590-02, Japan
- Department of Orthopaedic Surgery, Osaka University Medical School, Osaka, Japan
| |
Collapse
|
48
|
Sato R, Fujiya M, Watari J, Ueno N, Moriichi K, Kashima S, Maeda S, Ando K, Kawabata H, Sugiyama R, Nomura Y, Nata T, Itabashi K, Inaba Y, Okamoto K, Mizukami Y, Saitoh Y, Kohgo Y. The diagnostic accuracy of high-resolution endoscopy, autofluorescence imaging and narrow-band imaging for differentially diagnosing colon adenoma. Endoscopy 2011; 43:862-8. [PMID: 21732270 DOI: 10.1055/s-0030-1256510] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND AND STUDY AIMS Conventional colonoscopy can result in unnecessary biopsy or endoscopic resection due to its inability to distinguish adenomas from hyperplastic polyps. This study therefore evaluated the efficacy of high-resolution endoscopy (HRE), autofluorescence imaging (AFI), and narrow-band imaging (NBI) in discriminating colon adenoma from hyperplastic polyps. PATIENTS AND METHODS This was a prospective multicenter study in patients undergoing AFI and NBI examinations. HRE, AFI, and NBI images were classified into two groups based on morphological characteristics, the predominant color intensities, and the visibility of meshed capillary vessels, respectively. Each of the endoscopic photographs were independently evaluated by a single endoscopist. The images were then assessed by three specialists and three residents, the latter having performed < 500 colonoscopies and < 30 NBI and AFI examinations. Diagnostic test statistics were calculated to compare the accuracy in differentiating colon adenoma from hyperplastic polyps for each method. RESULTS A total of 183 patients were enrolled in the study and 339 adenomas and 85 hyperplastic polyps were identified. AFI and NBI could distinguish adenoma from hyperplastic polyps with an accuracy of 84.9 % and 88.4 %, respectively, whereas HRE exhibited an accuracy of 75.9 %. In the 358 lesions in which the AFI diagnosis was consistent with that of NBI, the accuracy, sensitivity, and specificity were high, at 91.9 %, 92.7 %, and 92.9 %, respectively. During the study comparing specialists and residents, AFI and NBI dramatically improved the diagnostic accuracy of residents from 69.1 % to 86.1 % and 84.7 %, respectively. CONCLUSIONS Both AFI and NBI are considered to be feasible tools that can discriminate colon adenoma from hyperplastic polyps, and their use may be particularly beneficial for less-experienced endoscopists.
Collapse
Affiliation(s)
- R Sato
- Internal Medicine, Engaru-Kosei General Hospital, Asahikawa, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Miura Y, Naito Y, Shimomura A, Iwatani T, Miura D, Kawabata H, Takano T. 3059 POSTER The Safety of Chemotherapy for Breast Cancer Patients With Hepatitis C Virus Infection. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71132-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
50
|
Ishibashi M, Naito Y, Miura Y, Takano T, Kishi K, Kitagawa H, Miura D, Kawabata H, Udagawa H. 1308 POSTER Paclitaxel-related Interstitial Lung Disease – Implication of Mediastinal Lymphadenopathy. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70882-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|